

## Suven Discovery Scientific Presentations in 2014

### **Alzheimer's Association International Conference (AAIC) Copenhagen, Denmark, July 13 - 16, 2014**

1. SUVN-I1307014: Novel M<sub>1</sub> muscarinic acetylcholine receptor positive allosteric modulator potential for the treatment of Alzheimer's disease.
2. SUVN-G3031: A novel and potent histamine H<sub>3</sub> receptor antagonist for potential treatment of cognitive deficits.
3. SUVN-D4010: Novel 5-HT<sub>4</sub> receptor partial agonist for the treatment of Alzheimer's disease.
4. *In-vivo* brain receptor occupancy for PDE-10 receptors in mice and rats using non-radiolabeled tracer.
5. Effect of gender and food on the single dose pharmacokinetics of SUVN-502, a potent and selective 5HT<sub>6</sub> receptor antagonist.
6. Influence of chronic pain on cognitive function: 5-HT<sub>6</sub> antagonist improves the behavioral outcome and attenuates the side effects of Gabapentin.
7. Effects of norepinephrine reuptake inhibitors on neurotransmitter modulations associated with cognitive dysfunction in chronic pain.